Brookline Capital Markets Comments on MNPR FY2026 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at Brookline Capital Markets lifted their FY2026 earnings estimates for Monopar Therapeutics in a report issued on Thursday, May 14th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings of ($2.88) per share for the year, up from their previous estimate of ($3.23). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($4.11) per share.

Several other research firms also recently weighed in on MNPR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Tuesday, April 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. BTIG Research reissued a “buy” rating and set a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Wall Street Zen raised shares of Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Chardan Capital reissued a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Monopar Therapeutics currently has a consensus rating of “Buy” and an average target price of $107.00.

Monopar Therapeutics Trading Down 5.1%

MNPR opened at $56.25 on Tuesday. Monopar Therapeutics has a 1-year low of $28.40 and a 1-year high of $105.00. The company has a market cap of $376.88 million, a P/E ratio of -29.61 and a beta of 1.49. The company has a fifty day moving average price of $56.97 and a two-hundred day moving average price of $65.54.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.41.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ally Bridge Group NY LLC boosted its holdings in Monopar Therapeutics by 86.6% during the third quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock worth $5,264,000 after purchasing an additional 29,918 shares during the last quarter. AlphaQuest LLC boosted its holdings in Monopar Therapeutics by 8.5% during the third quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock worth $158,000 after purchasing an additional 151 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in Monopar Therapeutics during the first quarter worth about $250,000. Sei Investments Co. boosted its holdings in Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Monopar Therapeutics by 21.2% during the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after purchasing an additional 13,761 shares during the last quarter. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.